Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Mar 2, 2020--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40 th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time. The Company is taking precautionary measures in response to the evolving coronavirus (COVID-19) situation in the Seattle area.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients’ lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200302005947/en/
Courtney Dugan, 212-257-6723
KEYWORD: WASHINGTON UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH OTHER SCIENCE GENERAL HEALTH RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Alpine Immune Sciences, Inc.
Copyright Business Wire 2020.
PUB: 03/02/2020 04:05 PM/DISC: 03/02/2020 04:05 PM